Skip to main content
Prometheus Raises $12 Billion to Propel Artificial Engineering in Biotech
← Docket
World

Prometheus Raises $12 Billion to Propel Artificial Engineering in Biotech

Prometheus has successfully secured $12 billion aimed at advancing artificial engineering in the biotech sector. This funding comes amidst notable developments, including Blood Cancer United's acquisition of a cancer drug.

Editorial Staff1 min read

Prometheus has announced a significant funding round, raising $12 billion to further its initiatives in artificial engineering within the biotechnology field.

This investment is part of a broader trend in the biotech industry, which includes the recent acquisition of a cancer drug by the nonprofit Blood Cancer United.

Additionally, companies like Lilly and Nvidia have made investments in Abridge, highlighting ongoing financial activity and interest in biotech advancements.

Updates

Update at 14:09 UTC on 2026-06-12

STAT reported Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news.

Sources: STAT